These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38061398)

  • 1. Differential profiles of serum cytokines in Parkinson's disease according to disease duration.
    Di Lazzaro G; Picca A; Boldrini S; Bove F; Marzetti E; Petracca M; Piano C; Bentivoglio AR; Calabresi P
    Neurobiol Dis; 2024 Jan; 190():106371. PubMed ID: 38061398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting.
    Youssef P; Hughes L; Kim WS; Halliday GM; Lewis SJG; Cooper A; Dzamko N
    Sci Rep; 2023 Mar; 13(1):5217. PubMed ID: 36997567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
    Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of task-oriented training combined with aerobic training on serum BDNF, GDNF, IGF-1, VEGF, TNF-α, and IL-1β levels in people with Parkinson's disease: A randomized controlled study.
    Soke F; Kocer B; Fidan I; Keskinoglu P; Guclu-Gunduz A
    Exp Gerontol; 2021 Jul; 150():111384. PubMed ID: 33965556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated Schwann cells and increased inflammatory cytokines IL-1β, IL-6, and TNF-α in patients' sural nerve are lack of tight relationship with specific sensory disturbances in Parkinson's disease.
    Zhang H; Wu J; Shen FF; Yuan YS; Li X; Ji P; Zhu L; Sun L; Ding J; Niu Q; Zhang KZ
    CNS Neurosci Ther; 2020 May; 26(5):518-526. PubMed ID: 31828965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Parkinson's disease-related pain with plasma interleukin-1, interleukin-6, interleukin-10, and tumour necrosis factor-α.
    Li D; Song X; Huang H; Huang H; Ye Z
    Neurosci Lett; 2018 Sep; 683():181-184. PubMed ID: 30063943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral blood inflammatory markers in early Parkinson's disease.
    Kim R; Kim HJ; Kim A; Jang M; Kim A; Kim Y; Yoo D; Im JH; Choi JH; Jeon B
    J Clin Neurosci; 2018 Dec; 58():30-33. PubMed ID: 30454693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tear levels of tumor necrosis factor-alpha in patients with Parkinson's disease.
    Çomoğlu SS; Güven H; Acar M; Öztürk G; Koçer B
    Neurosci Lett; 2013 Oct; 553():63-7. PubMed ID: 23973333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease.
    Dursun E; Gezen-Ak D; Hanağası H; Bilgiç B; Lohmann E; Ertan S; Atasoy İL; Alaylıoğlu M; Araz ÖS; Önal B; Gündüz A; Apaydın H; Kızıltan G; Ulutin T; Gürvit H; Yılmazer S
    J Neuroimmunol; 2015 Jun; 283():50-7. PubMed ID: 26004156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-α levels in CSF and serum in relation to the clinical diversity of Parkinson's disease.
    Karpenko MN; Vasilishina AA; Gromova EA; Muruzheva ZM; Miliukhina IV; Bernadotte A
    Cell Immunol; 2018 May; 327():77-82. PubMed ID: 29478949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Zishen pingchan granules combined with pramipexole on serum BDNF, IL-1β, IL-6, CRP, TNF-α levels in depressed patients with Parkinson's disease: Results of a randomized, double-blind, controlled study.
    Ning H; Zhou H; Yang N; Ren J; Wang H; Liu W; Zhao Y
    Exp Gerontol; 2023 Oct; 182():112295. PubMed ID: 37734668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine profiles of plasma extracellular vesicles as progression biomarkers in Parkinson's disease.
    Chan L; Chung CC; Yu RC; Hong CT
    Aging (Albany NY); 2023 Mar; 15(5):1603-1614. PubMed ID: 36897204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD).
    Niemann L; Lezius S; Maceski A; Leppert D; Englisch C; Schwedhelm E; Zeller T; Gerloff C; Kuhle J; Choe CU
    Parkinsonism Relat Disord; 2021 Sep; 90():44-48. PubMed ID: 34352610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease.
    Urso D; Batzu L; Logroscino G; Ray Chaudhuri K; Pereira JB
    Neurobiol Dis; 2023 Sep; 185():106237. PubMed ID: 37499883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
    Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
    Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson's disease.
    Fan Z; Pan YT; Zhang ZY; Yang H; Yu SY; Zheng Y; Ma JH; Wang XM
    J Neuroinflammation; 2020 Jan; 17(1):11. PubMed ID: 31915018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.
    Oosterveld LP; Verberk IMW; Majbour NK; El-Agnaf OM; Weinstein HC; Berendse HW; Teunissen CE; van de Berg WDJ
    Mov Disord; 2020 Feb; 35(2):288-295. PubMed ID: 31737952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum concentration and clinical significance of brain-derived neurotrophic factor in patients with Parkinson's disease or essential tremor.
    Huang Y; Yun W; Zhang M; Luo W; Zhou X
    J Int Med Res; 2018 Apr; 46(4):1477-1485. PubMed ID: 29350074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
    Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
    Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do peripheral immune and neurotrophic markers correlate with motor severity of Parkinson's disease?
    Roy A; Mondal B; Banerjee R; Choudhury S; Chatterjee K; Dey S; Kumar H
    J Neuroimmunol; 2021 May; 354():577545. PubMed ID: 33756415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.